Clinical Trial Update: Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase I/II trial evaluating the combination of 5-azacytidine with cytarabine in patients with relapsed/refractory acute myeloid leukemia or high-ris…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CYTARABINE (CYTARABINE)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2011-02-14